Journal article · 2026 · Open access

Anti-inflammatory CAR-microglia targeting Aβ for Alzheimer’s disease therapy

Xizhong Ding, Xukai Hu, Wanqiang Xue, Yingrui An, Wei Cheng, Shaolong Zhang, Anhua Lei, Jin Zhang

Frontiers in Immunology, 17, 1820099 · Published 14 July 2026 · DOI 10.3389/fimmu.2026.1820099

Open full textCite this paper

In brief

“Anti-inflammatory CAR-microglia targeting Aβ for Alzheimer’s disease therapy” is a 2026 journal article by Xizhong Ding and 7 co-authors, published in Frontiers in Immunology. OpenAlex counts 0 citations as of 18 November 2026. It is open access under a CC BY licence: the full text is free to read at Frontiers in Immunology.

Citations
0
References
34
Authors
8

Abstract

Alzheimer's disease (AD) is characterized by the accumulation of amyloid-β (Aβ) plaques and chronic neuroinflammation, which together drive progressive neuronal loss and cognitive decline. In recent years, monoclonal antibodies targeting Aβ have demonstrated encouraging clinical benefits in Alzheimer's disease (AD). However, their therapeutic efficacy remains limited by insufficient and unsustained clearance of Aβ, as well as treatment-associated neuroinflammatory responses. These limitations highlight the need for alternative strategies that can achieve efficient Aβ elimination while maintaining immune homeostasis. To overcome these challenges, we developed a novel anti-inflammatory CAR-Microglia (CAR-Mic) incorporating a construct based on the TAM receptor family (TYRO3, AXL, and MERTK), which are key regulators of efferocytosis and anti-inflammatory responses. The resulting Aβ-targeted CAR-Mics showed enhanced Aβ engulfment and reduced proinflammatory cytokines release. Among the constructs tested, AXL-CAR demonstrated the most favorable overall performance and was therefore selected for the generation of human induced pluripotent stem cell (iPSC)-derived CAR microglia-like cells (CAR-iMGLs). In an AD mouse model, AXL-CAR-iMGLs exhibited enhanced Aβ clearance without evidence of severe adverse effects. Collectively, these findings establish TAM receptor-based CAR-iMGLs as a promising cell therapy model for AD and potentially other neurodegenerative disorders characterized by chronic neuroinflammation and defective pathological protein clearance.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Ding, X., Hu, X., Xue, W., An, Y., Cheng, W., Zhang, S., Lei, A., & Zhang, J. (2026). Anti-inflammatory CAR-microglia targeting Aβ for Alzheimer’s disease therapy. Frontiers in Immunology, 17, 1820099. https://doi.org/10.3389/fimmu.2026.1820099

MLA 9

Ding, Xizhong, et al. “Anti-inflammatory CAR-microglia targeting Aβ for Alzheimer’s disease therapy.” Frontiers in Immunology, vol. 17, 2026, p. 1820099. https://doi.org/10.3389/fimmu.2026.1820099.

Chicago

Ding, Xizhong, Xukai Hu, Wanqiang Xue, Yingrui An, Wei Cheng, Shaolong Zhang, Anhua Lei, and Jin Zhang. 2026. “Anti-inflammatory CAR-microglia targeting Aβ for Alzheimer’s disease therapy.” Frontiers in Immunology 17: 1820099. https://doi.org/10.3389/fimmu.2026.1820099.

Harvard

Ding, X. et al. (2026) ‘Anti-inflammatory CAR-microglia targeting Aβ for Alzheimer’s disease therapy’, Frontiers in Immunology, 17, p. 1820099. doi:10.3389/fimmu.2026.1820099.

IEEE

X. Ding et al., “Anti-inflammatory CAR-microglia targeting Aβ for Alzheimer’s disease therapy,” Frontiers in Immunology, vol. 17, p. 1820099, 2026, doi: 10.3389/fimmu.2026.1820099.

BibTeX

@article{ding2026anti,
  title     = {{Anti-inflammatory CAR-microglia targeting Aβ for Alzheimer’s disease therapy}},
  author    = {Ding, Xizhong and Hu, Xukai and Xue, Wanqiang and An, Yingrui and Cheng, Wei and Zhang, Shaolong and Lei, Anhua and Zhang, Jin},
  journal   = {Frontiers in Immunology},
  year      = {2026},
  volume    = {17},
  pages     = {1820099},
  doi       = {10.3389/fimmu.2026.1820099},
  url       = {https://doi.org/10.3389/fimmu.2026.1820099}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments

  • Alzheimer's disease
  • amyloid-beta
  • TAM receptors
  • AXL
  • efferocytosis
  • neuroinflammation
  • amyloid-beta clearance
  • cell therapy

Work with this paper

Most-cited papers in Neuroscience

All highly cited Neuroscience papers

Questions about this paper

How do I cite this paper in APA style?

Ding, X., Hu, X., Xue, W., An, Y., Cheng, W., Zhang, S., Lei, A., & Zhang, J. (2026). Anti-inflammatory CAR-microglia targeting Aβ for Alzheimer’s disease therapy. Frontiers in Immunology, 17, 1820099. https://doi.org/10.3389/fimmu.2026.1820099

How many times has this paper been cited?

0 times, according to OpenAlex on 18 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Frontiers in Immunology: sign in and open the full text from this page.

Who wrote this paper?

Xizhong Ding, Xukai Hu, Wanqiang Xue, Yingrui An, Wei Cheng, Shaolong Zhang, Anhua Lei, Jin Zhang.

What is the DOI of this paper?

10.3389/fimmu.2026.1820099, permanently at https://doi.org/10.3389/fimmu.2026.1820099. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 18 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.